tiprankstipranks
Interpace Diagnostics Group (IDXG)
OTHER OTC:IDXG

Interpace Diagnostics Group (IDXG) Stock Price & Analysis

409 Followers

IDXG Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$0.77 - $3.54
Previous Close$1.12
Volume14.00
Average Volume (3M)4.90K
Market Cap
$4.90M
Enterprise Value$12.22M
Total Cash (Recent Filing)$3.50M
Total Debt (Recent Filing)$10.81M
Price to Earnings (P/E)5.3
Beta1.39
Aug 13, 2024
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.21
Shares Outstanding4,376,398
10 Day Avg. Volume5,290
30 Day Avg. Volume4,897
Standard Deviation0.35
R-Squared0.01
Alpha0.01
Financial Highlights & Ratios
Price to Book (P/B)-0.09
Price to Sales (P/S)0.14
Price to Cash Flow (P/CF)1.20
P/FCF Ratio1.40
Enterprise Value/Market CapN/A
Enterprise Value/Revenue0.36
Enterprise Value/Gross Profit0.51
Enterprise Value/Ebitda4.53
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0

Financials

Annual

Risk Analysis

Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy

Website Traffic

Sorry, No Data Available
There is no website visitor data available for this stock.
---

IDXG FAQ

What was Interpace Diagnostics Group’s price range in the past 12 months?
Interpace Diagnostics Group lowest stock price was $0.77 and its highest was $3.54 in the past 12 months.
    What is Interpace Diagnostics Group’s market cap?
    Currently, no data Available
    When is Interpace Diagnostics Group’s upcoming earnings report date?
    Interpace Diagnostics Group’s upcoming earnings report date is Aug 13, 2024 which is in 39 days.
      How were Interpace Diagnostics Group’s earnings last quarter?
      Interpace Diagnostics Group released its earnings results on May 09, 2024. The company reported $0.107 earnings per share for the quarter, beating the consensus estimate of N/A by $0.107.
        Is Interpace Diagnostics Group overvalued?
        According to Wall Street analysts Interpace Diagnostics Group’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
          Does Interpace Diagnostics Group pay dividends?
          Interpace Diagnostics Group does not currently pay dividends.
          What is Interpace Diagnostics Group’s EPS estimate?
          Interpace Diagnostics Group’s EPS estimate for its next earnings report is not yet available.
          How many shares outstanding does Interpace Diagnostics Group have?
          Interpace Diagnostics Group has 4,376,398 shares outstanding.
            What happened to Interpace Diagnostics Group’s price movement after its last earnings report?
            Interpace Diagnostics Group reported an EPS of $0.107 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 3.571%.
              Which hedge fund is a major shareholder of Interpace Diagnostics Group?
              Currently, no hedge funds are holding shares in IDXG
              ---

              Interpace Diagnostics Group Stock Smart Score

              10
              Unlock Smart Score
              1
              2
              3
              4
              5
              6
              7
              8
              9
              10

              Fundamentals

              Return on Equity
              Trailing 12-Months
              Asset Growth
              -23.52%
              Trailing 12-Months

              Company Description

              Interpace Diagnostics Group

              Interpace Biosciences, Inc. operates as an bioinformatics company, which engages in the development and commercialization of molecular diagnostic test and pathology services. It offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion molecular test that can aid in pancreatic cyst diagnosis and pancreatic cancer risk assessment; ThyGenX and PathFinderTG which assesses thyroid nodules for risk of malignancy; and ThyraMIR, which assesses thyroid nodules for risk of malignancy utilizing a proprietary gene expression assay. The company was founded by John P. Dugan in 1987 and is headquartered in Parsippany, NJ.
              ---
              Similar Stocks
              Company
              Price & Change
              Follow
              Cellectar Biosciences
              Cidara Therapeutics
              PAVmed
              OpGen
              Popular Stocks
              ---
              What's Included in PREMIUM?
              Make informed decisions based on Top Analysts' activity
              Know what industry insiders are buying
              Get actionable alerts from top Wall Street Analysts
              Find out before anyone else which stock is going to shoot up
              Get powerful stock screeners & detailed portfolio analysis